On June 24, 2014 , the Indian Patent Office (IPO) refused to grant a patent for Abraxane®, the anti-cancer drug developed by the US firm Abraxis Biosciences (hereinafter referred as Abraxis), for the second time.
The most radical change in EPO in over 40 years was the introduction of “Unitary Patent Package” legislation that proposed a Unitary Patent System and a Unitary Patent Court open for participation for all member states of the European Union.
In India, a patent may be invalidated in three ways, namely, by post grant opposition, by revocation proceedings before the Intellectual Property Appellate Board (IPAB) and by a counter-claim in an infringement suit before a High Court (HC).
The process of patenting an invention may be a cumbersome process with respect to the procedures involved from the filing of a patent application to the grant/abandonment of the patent application. Once the patent application is filed, it moves through several stages before getting a grant.
Indian Patent Office Rejects Abraxane Patent Application for the Second Time
The European Unitary Patent Package
Supreme Court Addresses Issues of Multiplicity of Proceedings in Patent Disputes
Fast Tracking Examination
Anti-Patent Troll Bill